All In Biotech

Drug Trial Radar · NCT05983783

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

A Prospective Randomized Controlled Study Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the Treatment of Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Aug 1, 2023

Primary completion

Dec 31, 2025

Study completion Dec 31, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Aug 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate whether the combination of Rezvilutamide and androgen deprivation therapy (ADT) with docetaxel improves overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to the combination of Rezvilutamide and ADT.

Conditions

  • Metastatic Prostate Cancer
  • Hormone Sensitive Prostate Cancer
  • Chemotherapy Effect

Interventions

  • DocetaxelDrug

    This is Triple drug regimen for mHSPC

  • RezvilutamideDrug

    This is doubling drug regimen for mHSPC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rPFSTime frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Urology dpt, First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.